Australian Clinical Labs Ltd (AU:ACL) has released an update.
JPMorgan Chase & Co. and its affiliates have become substantial shareholders in Australian Clinical Labs Ltd, with a 5.27% stake as of June 20, 2024. The shares include various forms of holdings such as securities on loan and obligations to return under securities lending agreements. This move reflects JPMorgan’s investment strategy and interest in the Australian medical diagnostics company.
For further insights into AU:ACL stock, check out TipRanks’ Stock Analysis page.
